Drugs / TLC-6740
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05822544 | Apr 2023 → Feb 2026 overdue | obesity disorder, type 2 diabetes mellitus | OrsoBio, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | OrsoBio, Inc | Results OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions orsobio.com ↗
The randomized, double-blind, placebo-controlled study demonstrated significant improvements in weight loss, insulin sensitivity, liver health, and body composition compared with tirzepatide monotherapy. |
| 2025-12-16 | OrsoBio, Inc | Results OrsoBio Announces Positive Topline Phase 1b/2a Clinical Data for its Oral Mitochondrial Protonophore TLC-6740 in Combination with Tirzepatide orsobio.com ↗
At week 24, participants receiving TLC-6740 plus tirzepatide achieved mean weight loss of 13.3%, compared with 8.8% with tirzepatide alone. |
| 2025-11-04 | OrsoBio, Inc | Results OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 2025 orsobio.com ↗
Co-administration with a proton pump inhibitor (omeprazole) or a high-fat, high-calorie meal did not meaningfully alter TLC-6740’s PK profile or safety. |
| 2025-06-20 | OrsoBio, Inc | Results OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association’s 85th Scientific Sessions orsobio.com ↗
The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. |
| 2024-06-21 | OrsoBio, Inc | Results OrsoBio to Present Phase 1 and Preclinical Data for Liver-Targeted Mitochondrial Protonophore TLC-6740 at the American Diabetes Association’s 84th Scientific Sessions orsobio.com ↗
Phase 1 data confirm the safety of TLC-6740, dose-dependent increases in energy expenditure, and improvements in plasma lipids and markers of insulin resistance |
| 2023-10-16 | OrsoBio, Inc | Results OrsoBio to Present Phase 1 Data for the Liver-Targeted Mitochondrial Protonophore TLC-6740 in Development for the Treatment of Obesity at ObesityWeek® 2023 orsobio.com ↗
OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced preliminary safety and pharmacokinetic (PK) data from the single ascending dose (SAD) portion of an ongoing Phase 1 trial of TLC-6740, a liver-targeted, mitochondrial protonophore. |
| 2023-06-05 | OrsoBio, Inc | Results OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases orsobio.com ↗
TLC-6740 has been well tolerated in the first two single-dose cohorts and preliminary pharmacokinetic (PK) data support once-daily dosing. |
| 2022-11-03 | OrsoBio, Inc | Results OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders orsobio.com ↗
In vitro, mild hepatic mitochondrial uncoupling with TLC-6740 was associated with metabolic benefits in multiple cell types, including AMPK activation, increased TCA cycle flux, and inhibition of de novo lipogenesis. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLC-6740 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05822544 ↗ |
| Route | Oral | “Oral solution of TLC-6740” NCT05822544 ↗ |